公开(公告)号：US20210137939A1

公开(公告)日：2021-05-13

申请号：US17053057

申请日：2019-05-10

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Geoffrey J. Clark ,  John O. Trent ,  Joseph A. Burlison

IPC: A61K31/55 ,  A61K31/40 ,  A61K31/357

Abstract: A compound for use in treating a disease associated with activating mutations in RAS, or for use in treating a disease treatable by a reduction in RAS activity, is selected from a compound of Formula (I), salts and esters thereof. The compounds are particularly useful in treating cancer.

公开(公告)号：US11312690B2

公开(公告)日：2022-04-26

申请号：US15746819

申请日：2016-07-22

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Geoffrey J. Clark ,  John O. Trent ,  Joseph A. Burlison ,  Nagaraju Miriyala

IPC: C07D239/95 ,  A61P35/04

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.